يعرض 1 - 10 نتائج من 33 نتيجة بحث عن '"M.P. Sablin"', وقت الاستعلام: 1.22s تنقيح النتائج
  1. 1
    Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer

    المؤلفون: M. Campone, Bojana Stefanovska, Alexandra Jacquet, Fabrice Andre, M.P. Sablin, Hervé Bonnefoi, C. Le Tourneau, Isabelle Miran, Florence Dalenc, Cécile Jovelet, Thomas Bachelot, Amélie Lusque, F. Mosele, Nathalie Droin, A. Tran Dien, François Bertucci, Ivan Bièche, Diego Enrico, Ingrid Garberis, Jean-Charles Soria, M. Jimenez, Ludovic Lacroix

    المصدر: Annals of Oncology. 31:377-386

    مصطلحات موضوعية: 0301 basic medicine, Oncology, medicine.medical_specialty, Class I Phosphatidylinositol 3-Kinases, Receptor, ErbB-2, medicine.medical_treatment, Outcome analysis, Breast Neoplasms, Triple Negative Breast Neoplasms, Phosphatidylinositol 3-Kinases, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, Internal medicine, Biomarkers, Tumor, medicine, Humans, In patient, Digital polymerase chain reaction, skin and connective tissue diseases, neoplasms, Chemotherapy, business.industry, Pik3ca mutation, Hematology, Prognosis, medicine.disease, Metastatic breast cancer, 030104 developmental biology, 030220 oncology & carcinogenesis, Mutation, business, Hormone

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06d97071590d7c260bba7e9e12d628b1
    https://doi.org/10.1016/j.annonc.2019.11.006

    أضف إلى المفضلة
  2. 2
    781TiP AGADIR: A basket multicenter open-label phase II study evaluating the first in class TLR7/8 agonist BDB001 in combination with atezolizumab and stereotactic body radiation therapy in patients with advanced solid tumors

    المؤلفون: A. Italiano, C. Coutzac Bergouignan, D. Pasquier, P. Rochigneux, M.P. Sablin, C.A. Gomez-Roca, F. Ghiringhelli, J-P. Metges, M. Toulmonde, S. Cousin, S. Pernot, C. Auzanneau, B. Lortal, M. Kind, P. Sargos, S. Batard, A. Petit, P. Gillon, S. Albert, M. Pulido

    المصدر: Annals of Oncology. 33:S898

    مصطلحات موضوعية: Oncology, Hematology

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::c93351c80d81bdb9bf22c940d8836c7c
    https://doi.org/10.1016/j.annonc.2022.07.907

    أضف إلى المفضلة
  3. 3
    Abstract P6-21-01: Xentuzumab (BI 836845), an insulin-like growth factor (IGF)-neutralizing antibody (Ab), combined with exemestane and everolimus in hormone receptor-positive (HR+) locally advanced/metastatic breast cancer (LA/mBC): Randomized phase 2 results

    المؤلفون: R-M Espadero, Joop P. W. van den Bergh, Jose Alejandro Perez-Fidalgo, A. Gonçalves, Serafin Morales, Peter Schmid, D Adamson, KS Lee, Aleix Prat, Patrick Neven, Noelia Martínez, G. Jerusalem, Y-S Lu, S-A Im, J. Cortés, J.P. Crown, L Schlieker, Thomas Bogenrieder, D Chin-Lun Huang, M.P. Sablin

    المصدر: Cancer Research. 79:P6-21

    مصطلحات موضوعية: 0301 basic medicine, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Population, Urology, 03 medical and health sciences, chemistry.chemical_compound, Insulin-like growth factor, 0302 clinical medicine, Breast cancer, Exemestane, Medicine, education, education.field_of_study, Everolimus, business.industry, Cancer, medicine.disease, Interim analysis, Metastatic breast cancer, 030104 developmental biology, Oncology, chemistry, 030220 oncology & carcinogenesis, business, medicine.drug

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::5e8374df546edd4ff7db37d80ba9c6a9
    https://doi.org/10.1158/1538-7445.sabcs18-p6-21-01

    أضف إلى المفضلة
  4. 4
    Phase 1b study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab (Atezo), and paclitaxel (PAC) or nab-PAC as first-line (1L) therapy for locally advanced/metastatic triple-negative breast cancer (aTNBC)

    المؤلفون: V Boni, Matthew Wongchenko, S Kümmel, P Schmid, Stina M. Singel, Peter Savas, M.P. Sablin, A Italiano, Delphine Loirat, Adam Harris, S Li, Shane White, E Espinosa, N Withana, Aruna Mani

    المصدر: Senologie - Zeitschrift für Mammadiagnostik und -therapie.

    مصطلحات موضوعية: chemistry.chemical_compound, Paclitaxel, chemistry, business.industry, Atezolizumab, First line, Phase (matter), Locally advanced, Cancer research, Medicine, business, Ipatasertib, Triple-negative breast cancer

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2a4a08509cf4318ec48c7b25d89ac6e
    https://doi.org/10.1055/s-0040-1710644

    أضف إلى المفضلة
  5. 5
    Abstract P5-21-05: Withdrawn

    المؤلفون: David M. Hyman, DJ Renouf, Anthony B. El-Khoueiry, Marcos Vinicius Silva Oliveira, J. Baselga, Kazuo Tamura, IA Mayer, J. Lindemann, Rhiannon Maudsley, Benoit You, Helen Ambrose, Udai Banerji, A Rutkowski, Gaia Schiavon, H Yamashita, TH Carr, A. Lluch, Alain C. Mita, E. De Bruin, Claire Corcoran, L.M. Smyth, Andrew Foxley, Martin Pass, S Chandarlapaty, Hideaki Bando, Eva Ciruelos, M Scaltriti, M.P. Sablin, Barry S. Taylor

    المصدر: Cancer Research. 78:P5-21

    مصطلحات موضوعية: Cancer Research, Oncology

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::166c98f0cce9aaedda8efa73d21f43ab
    https://doi.org/10.1158/1538-7445.sabcs17-p5-21-05

    أضف إلى المفضلة
  6. 6
    Abstract OT3-06-02: A phase Ib trial of xentuzumab and abemaciclib in patients with locally advanced or metastatic solid tumors, including hormone receptor-positive, HER2-negative breast cancer (plus endocrine therapy)

    المؤلفون: Aleix Prat, J. Serra, Hiroji Iwata, M.P. Sablin, H Hua, Douglas Yee, E.L. Johnston, P. Lo Russo, Thomas Bogenrieder

    المصدر: Cancer Research. 78:OT3-06

    مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, Fulvestrant, business.industry, Letrozole, Anastrozole, Cancer, Palbociclib, medicine.disease, Breast cancer, Tolerability, Internal medicine, Cohort, Medicine, business, medicine.drug

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::4e73e468e9f0c9eb25ba5a0d6a218829
    https://doi.org/10.1158/1538-7445.sabcs17-ot3-06-02

    أضف إلى المفضلة
  7. 7
    75P Tumor mutational burden in clinical routine practice: Identifying the right threshold?

    المؤلفون: J. Wong, Ivan Bieche, C. Le Tourneau, P. du Rusquec, Celia Dupain, Coralie Franck, Cindy Neuzillet, Elodie Girard, Nicolas Servant, Maud Kamal, Joanna Cyrta, M. Galut, Anne Vincent-Salomon, M.P. Sablin, Yves Allory, Julien Masliah-Planchon, Samantha Antonio, I. Guillou, P. Tresca, T. Gutman

    المصدر: Annals of Oncology. 32:S388

    مصطلحات موضوعية: medicine.medical_specialty, Oncology, business.industry, Medicine, Hematology, business, Intensive care medicine, Clinical routine

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::990db65bb8a830a9ca28d4f2c490b401
    https://doi.org/10.1016/j.annonc.2021.08.355

    أضف إلى المفضلة
  8. 8
    Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial

    المؤلفون: Nicolas Isambert, Cecile Mauborgne, A. Gonçalves, Delphine Loirat, Vincent Servois, M.P. Sablin, C. Plancher, F. Mulot, Coraline Dubot, Olivier Tredan, Francesco Ricci, Jean-P. Delord, Céline Gavoille, Maud Kamal, M. Campone, Lisa Belin, Xavier Paoletti, C. Le Tourneau, Marie Alt

    المساهمون: Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)

    المصدر: Annals of Oncology
    Annals of Oncology, Elsevier, 2016, ⟨10.1093/annonc/mdw666⟩
    Europe PubMed Central

    مصطلحات موضوعية: Adult, Male, 0301 basic medicine, Oncology, medicine.medical_specialty, Randomization, Genotype, Patients, Survival, analysis, medicine.medical_treatment, Phases of clinical research, [SDV.CAN]Life Sciences [q-bio]/Cancer, Pharmacology, Medical Oncology, Disease-Free Survival, methods, Targeted therapy, 03 medical and health sciences, 0302 clinical medicine, Neoplasms, Internal medicine, Clinical endpoint, medicine, Humans, In patient, Molecular Targeted Therapy, Progression-free survival, Precision Medicine, Aged, Aged, 80 and over, Cross over, therapy, Cross-Over Studies, business.industry, Patient Selection, Standard of Care, Hematology, Middle Aged, 3. Good health, 030104 developmental biology, Response Evaluation Criteria in Solid Tumors, 030220 oncology & carcinogenesis, Disease Progression, Female, France, Radiology, business

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ea121032cc2327d1d44cf3f223212d66
    https://doi.org/10.1093/annonc/mdw666

    أضف إلى المفضلة
  9. 9
    Abstract PD1-08: High-throughput genome analysis and therapeutic decision for patients with HER2-negative metastatic breast cancer: First feasibility and molecular results of the randomized phase II study SAFIR02 BREAST (UCBG-0105/1304)

    المؤلفون: M. Jimenez, J-M Ferrero, Gaëlle Pierron, Frédéric Commo, Pascal Jézéquel, Amélie Lusque, V Attignon, A. Gonçalves, M. Campone, Ludovic Lacroix, C. Lefeuvre-Plesse, Florence Dalenc, Monica Arnedos, Isabelle Soubeyran, Thomas Bachelot, Ivan Bièche, Hervé Bonnefoi, M.P. Sablin, F Andre, Thomas Filleron

    المصدر: Cancer Research. 77:PD1-08

    مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, Bicalutamide, business.industry, medicine.medical_treatment, Cancer, Phases of clinical research, medicine.disease, Metastatic breast cancer, Olaparib, Targeted therapy, chemistry.chemical_compound, Breast cancer, chemistry, Internal medicine, medicine, Selumetinib, business, medicine.drug

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::73052e4b1b9519fe4d5ca076fc50fbea
    https://doi.org/10.1158/1538-7445.sabcs16-pd1-08

    أضف إلى المفضلة
  10. 10
    Reanalysis of the efficacy of molecular targeted agents (MTAs) given in the randomized trial SHIVA01 according to the ESMO ESCAT scale of actionability

    المؤلفون: Anne Vincent Salomon, Nouritza Torossian, Aurelie Moreira, Maud Kamal, Francesco Ricci, Ségolène Hescot, Sophie Vacher, Ivan Bièche, Julien Masliah-Planchon, Edith Borcoman, Maxime Frelaut, Delphine Loirat, Charlotte Lecerf, M.P. Sablin, C. Le Tourneau, Céline Callens

    المصدر: Annals of Oncology. 30:v27-v28

    مصطلحات موضوعية: Oncology, medicine.medical_specialty, Standard of care, business.industry, Cancer, Hematology, medicine.disease, Precision medicine, Chemotherapy regimen, law.invention, Log-rank test, Randomized controlled trial, law, Internal medicine, medicine, Molecular targets, Progression-free survival, business

    URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::4ac82f4fffaa0fcb7596aa1711766a3f
    https://doi.org/10.1093/annonc/mdz239.008

    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS – أرسل هذا البحث بالبريد الإلكتروني – حفظ البحث – جدول التنبيهات: لا شيء